Table 1.
Baseline clinical characteristics in each study group.
| (+) OSA (+) PVI (+) triggers (n=43) | (−) OSA (+) PVI (+) triggers (n=43) | (−) OSA (+) PVI (−) triggers (n=48) | (+) OSA (+) PVI (−) triggers (n=50) | P value* | |
|---|---|---|---|---|---|
| Male gender | 28 (65.1) | 22 (51.1) | 27 (56.2) | 33 (66.0) | |
| Age, years | 49±12 | 54±14 | 59±12 | 51±15 | 0.42 |
| BMI, kg/m2 | 31±6 | 29±7.5 | 26±9.0 | 32±5.5 | 0.23 |
| Hypertension | 21 (48.8) | 18 (41.8) | 18 (37.5%) | 27(54.0) | 0.62 |
| AF duration (years) | 6.0 (2–8) | 5.5 (1–14) | 4.0 (1–14) | 4.5 (2–7) | 0.30 |
| Frequency(episodes/mon) | 3 (0–4) | 2 (1–5) | 2 (1–4) | 3 (1–6) | |
| Number of failed AADs | 0.8 (0–2) | 0.7 (0–2) | 0.5 (0–3) | 0.4 (0–2) | 0.41 |
| Echocardiographic data | |||||
| LA area indexed BSA (cm2/m2) | 13.2±3.1 | 8.8±1.8 | 9.6±2.4 | 11.2±2.1 | 0.03 |
| LVEF (%) | 60±5 | 62±2 | 63±8 | 60±5 | 0.7 |
| Polysomnography data | |||||
| Mean AHI | 36±26 | 3±2 | 4±2 | 33±22 | <0.0001 |
| Desaturations ≥4%/h (no) | 28±16 | 3±3 | 2±2 | 26±12 | <0.0001 |
*
P-value for one-way ANOVA (Kruskal-Wallis) among all groups
PVI, pulmonary vein isolation; BMI, body mass index; PAF, paroxysmal AF; AAD, anti-arrhythmic drugs; LA, left atrium; BSA, body surface area; LVEF, left ventricular ejection fraction; AHI, apnea-hypopnea index.